| ¿µ¹® | coagulation necrosis | ÇÑ±Û | ÀÀ°í±«»ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ Á×À½À» ³ªÅ¸³»´Â ÇüÅÂÇÐÀû º¯È·Î¼ ±«»çºÎÀ§°¡ ÀÀ°íÇÑ »óÅ·ΠÀÖ´Â °Í. ±«»ç¼¼Æ÷´Â È£»ê¼º µ¢¾î¸®·Î º¸À̸ç Àû¾îµµ ¼öÀϰ£ ¼¼Æ÷ÀÇ ±âº» À±°ûÀÌ º¸Á¸µÇ±â ¶§¹®¿¡ Á¶Á÷±¸Á¶¸¦ ½Äº°ÇÒ ¼ö ÀÖ´Ù. ´ëÇ¥ÀûÀ¸·Î ÇãÇ÷±«»ç¸¦ µé ¼ö ÀÖ´Ù. °æ»ö°ú ÇãÇ÷¿¡ ÀÇÇÑ Àú»ê¼ÒÁõ½Ã ½ÉÀå±ÙÀ̳ª ÄáÆÏ¿¡¼ °üÂûµÇ°Å³ª Àü±â ¹× ¼öÀºÁßµ¶½Ã ÄáÆÏÀÇ ¿ä¼¼°ü¿¡¼ °üÂûµÇ´Â °ÍÀ¸·Î ´Ü¹éÀÇ º¯¼º ÈÄ ³²¾ÆÀֱ⠶§¹®ÀÌ´Ù. ¼¼Æ÷ÀÇ À±°ûÀÌ ³²¾Æ ÀÖ¾î ¿ø·¡ Á¶Á÷ÀÇ ±¸Á¶¸¦ ÇüÅÂÇÐÀûÀ¸·Î ÀνÄÇÒ ¼ö ÀÖ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. |
||
| ¿µ¹® | coagulation time | ÇÑ±Û | ÀÀ°í½Ã°£ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù. ù¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ Ç÷¾×¼Ó¿¡ ÀÖ´Â ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ´Â °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼ Çϳª·Î ¸¸³ª¼ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù. |
||
| ¿µ¹® | fasting blood sugar | ÇÑ±Û | °øº¹Ç÷´ç, ºó¼ÓÇ÷´ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾×¼Ó¿¡ Æ÷ÇԵǾî ÀÖ´Â Æ÷µµ´ç. ³ú¿Í ÀûÇ÷±¸ÀÇ ¿¡³ÊÁö¿øÀÌ µÇ°í, ±× ¾çÀº ¿îµ¿, ½Ä»ç µûÀ§¿¡ ÀÇÇÏ¿© ´Þ¶óÁø´Ù. °Ç°ÀÎÀÇ ¾ÆÄ§ °øº¹½Ã Ç÷Áß Æ÷µµ´ç ³óµµ´Â 60~100mg/dLÀÌÁö¸¸ ±âŸÀÇ ´çÁú Áï °ú´ç, °¥¶ôÅ佺, 5ź´çÀº ¹Ì·®À̸ç ÀϹÝÀûÀ¸·Î Ç÷´çÀÏ Çϸé Ç÷Á߯÷µµ´çÀ» ÀǹÌÇÑ´Ù. Ç÷´çÀº »ýüÀÇ ¿¡³ÊÁö¿øÀ¸·Î¼ °¡Àå Áß¿äÇÑ ¹°ÁúÀÌ´Ù. ±× ³óµµ´Â âÀÚ°üÀ¸·ÎºÎÅÍÀÇ Èí¼ö, °£¿¡ ÀÖ¾î¼ÀÇ ´ç½Å»ý°ú ±Û¸®ÄÚ°ÕÀÇ ÇÕ¼º-ºÐÇØ, ¸»ÃÊÁ¶Á÷ÀÇ ´çÀÌ¿ë, ÄáÆÏÀ¸·ÎºÎÅÍÀÇ ¹è¼³ µî ¿©·¯ ÀÎÀÚ¿¡ÀÇÇØ Á¿ìµÇ¸ç ±× Á¶Àý¿¡´Â ÀÚÀ²½Å°æ°ú °¢Á¾ È£¸£¸óÀÌ ¹ÐÁ¢ÇÏ°Ô °ü°èÇÑ´Ù. ƯÈ÷ Ç÷´çÀúÇÏÀÛ¿ë¿¡´Â Àν¶¸°ÀÌ, ±×¸®°í Ç÷´ç»ó½ÂÀÛ¿ë¿¡´Â ¿¡Çdz×ÇÁ¸°, ±Û·çÄ«°ï, ¼ºÀåÈ£¸£¸ó, ºÎ½Å°ÑÁúÈ£¸£¸ó, ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó, °©»ó»ù È£¸£¸óÀÌ °ü°è°¡ ÀÖÀ¸¸ç ±×°ÍµéÀÇ ´ëÇ× ¹× ÇùÁ¶ ÀÛ¿ë¿¡ ÀÇÇØ Ç÷´çÄ¡°¡ Á¶ÀýµÈ´Ù. |
||
| ¿µ¹® | white blood cell(WBC), leukocyte | ÇÑ±Û | ¹éÇ÷±¸ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, ȤÀº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀÎ Çö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù. |
||
| ¿µ¹® | whole blood | ÇÑ±Û | ÀüÇ÷, ¿ÂÇ÷¾× |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÇ ¸ðµç ¼ººÐÀÌ Çϳªµµ Á¦°ÅµÇÁö ¾ÊÀº ¿ÂÀüÇÑ Ç÷¾×. ÀüÇ÷Àº ¾ö°ÝÇÑ ¹«±ÕÁ¶°ÇÇÏ¿¡¼, ¼±º°ÇÑ °øÇ÷ÀڷκÎÅÍ Ã¤ÃëÇÑ °ÍÀ̸ç, ±¸¿¬»ê ÀÌ¿ÂÀ̳ª ÇìÆÄ¸° °°Àº Ç×ÀÀ°øÁ¦·Î ÀÀ°í¸¦ ¹æÁöÇÏ¿© Ç÷¾×º¸Ãæ ¸ñÀûÀ¸·Î »ç¿ëÇÑ´Ù. |
||
| F2R | [blood coagulation] factor II receptor |
|---|---|
| CCF | cancer coagulation factor; cardiolipin complement fixation; carotid-cavernous fistula; centrifuged c... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| SF | Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f... |
| TF | free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ... |
| LACI | Lipoprotein Associated Coagulation Inhibitor |
|---|---|
| MCT | Microwave coagulation therapy |
| PMCT | Percutaneous microwave coagulation therapy |
| DIC | diffuse intravascular coagulation |
| PEG-rHuMGDF | PEGylated recombinant human megakaryocyte growth and development factor |
| light coagulation | The coagulation of tissue by an intense beam of light, including laser (laser coagulation). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, haemorrhages, and malignant and benign neoplasms. (12 Dec 1998) |
|---|---|
| lipoprotein-associated coagulation inhibitor | Formerly known as anticonvertin; a protein that inhibits the extrinsic pathway of coagulation by binding to the tissue factor III-factor VII-Calcium-factor Xa complex. (05 Mar 2000) |
| lupus coagulation inhibitor | An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications. (12 Dec 1998) |
| blood clotting factor | <haematology> Any of a number of different protein factors which, when acting together, can form a blood clot shortly after platelets have broken at the site of the wound. The factors have Roman numeral names, like VII, VIII, IX, X, XI, and XIII. Defects in the genes which code for any of these factors result in genetic diseases like haemophilia, which results from a defect in the gene for factor VIII or IX. (09 Oct 1997) |
| recombinant | <molecular biology> A cell or an individual with a new combination of genes not found together in either parent, usually applied to linked genes. (18 Nov 1997) |
| recombinant clone | <molecular biology> Clones containing recombinant DNA molecules. See: recombinant DNA technologies. (14 Oct 1997) |
| recombinant clones | Clones containing recombinant DNA molecules. (12 Dec 1998) |
| recombinant DNA | <molecular biology> Spliced DNA formed from two or more different sources that have been cleaved by restriction enzymes and joined by ligases. (18 Nov 1997) |
| recombinant DNA molecules | A combination of DNA molecules of different origin that are joined using recombinant DNA technology. (12 Dec 1998) |
| recombinant DNA technologies | Procedures used to join together DNA segments in a cell-free system (an environment outside a cell ororganism). Under appropriate conditions, a recombinant DNA molecule canenter a cell and replicate there, either autonomously or after it hasbecome integrated into a cellular chromosome. (09 Oct 1997) |
| recombinant DNA technology | A series of procedures used to join together (recombine) DNA segments. A recombinant DNA molecule is constructed (recombined) from segments from 2 or more different DNA molecules. Under certain conditions, a recombinant DNA molecule can enter a cell and replicate there, autonomously (on its own) or after it has become integrated into a chromosome. (12 Dec 1998) |
| recombinant fusion proteins | Proteins that are the result of genetic engineering. A regulatory part or promoter of one or more genes is combined with a structural gene. The fusion protein is formed after transcription and translation of the fused gene. This type of fusion protein is used in the study of gene regulation or structure-activity relationships. They might also be used clinically as targeted toxins (immunotoxins). (12 Dec 1998) |
| recombinant proteins | Proteins prepared by recombinant DNA technology. (12 Dec 1998) |
| recombinant strain | <molecular biology> A cell or an individual with a new combination of genes not found together in either parent, usually applied to linked genes. (18 Nov 1997) |
| recombinant vector | A vector into which a foreign DNA has been inserted. Synonym: vector. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|